New Study Reveals Gradual Reduction of Ozempic Prevents Weight Rebound

Recent research shows a structured tapering of anti-obesity drugs like Ozempic and Wegovy can maintain weight loss, challenging previous long-term dependency concerns.

• A Danish study indicates that slowly decreasing doses of semaglutide, a key ingredient in Ozempic, helps sustain weight loss after discontinuation.
• Patients managed to maintain their weight for six months post-treatment by combining drug tapering with lifestyle adjustments.
• Initial lower dosages of the medication proved equally effective, reducing side effects and dependency risks.
• The study's findings could reshape treatment protocols, potentially alleviating drug shortages by optimizing dosage.
• Experts emphasize the importance of integrating dietary and exercise guidance to support long-term weight management.

3 Articles

The Telegraph Fortune Evening Standard